Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trifast trades in line YTD despite 'continuing external market challenges'

(Sharecast News) - Engineered fastening business Trifast said on Thursday that its year-to-date performance was in line with expectations, driven by margin recovery and progress on its medium-term strategy. Trifast said trading in the first four months of FY26 was in line with internal expectations, even as macroeconomic headwinds remained, impacting certain industrial markets.

The London-listed group stated that its focus remained on self-help levers to deliver further margin improvement as it looks to transform our business into an "efficient, professional and data-led" one.

"The success to date of our Recover, Rebuild, Resilience turnaround strategy gives the board confidence that we will be able to deliver our objectives of margin growth and improved cash generation despite the industrial backdrop," said Trifast. "Today, Trifast is a leaner, more focused and better business. Whilst there is more to accomplish, we are excited about the future potential of the business as we look to the next chapter of its growth."

Looking ahead, Trifast said that despite "continuing external market challenges", it remains confident in delivering its medium-term ambitions, including an EBIT margin target of more than 10%.

As of 0930 BST, Trifast shares were up 1.37% at 88.80p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.